News
AKTX
5.70
0.00%
0.00
Akari: Buy Rating Reiterated as AKTX-101 Advances Toward Phase 1; $27 Price Target Unchanged
TipRanks · 2d ago
Weekly Report: what happened at AKTX last week (1109-1113)?
Weekly Report · 2d ago
Akari Therapeutics reports Q3 results
Seeking Alpha · 4d ago
Weekly Report: what happened at AKTX last week (1102-1106)?
Weekly Report · 11/09 10:22
Weekly Report: what happened at AKTX last week (1026-1030)?
Weekly Report · 11/02 10:21
Akari Therapeutics Expands 2023 Equity Incentive Share Pool
TipRanks · 10/30 21:35
Weekly Report: what happened at AKTX last week (1019-1023)?
Weekly Report · 10/26 10:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/19 12:05
Weekly Report: what happened at AKTX last week (1012-1016)?
Weekly Report · 10/19 10:21
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/19 08:46
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/14 21:06
Weekly Report: what happened at AKTX last week (1005-1009)?
Weekly Report · 10/12 10:27
Weekly Report: what happened at AKTX last week (0928-1002)?
Weekly Report · 10/05 10:26
Akari Therapeutics Enhances CEO Compensation, Equity Incentives
TipRanks · 10/01 21:20
Analysts’ Top Healthcare Picks: Akari Therapeutics (AKTX), Corcept Therapeutics (CORT)
TipRanks · 10/01 14:40
Akari Therapeutics expands IP portfolio with PCT filing for ADC payload
TipRanks · 10/01 12:36
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Benzinga · 10/01 12:26
Weekly Report: what happened at AKTX last week (0921-0925)?
Weekly Report · 09/28 10:21
Weekly Report: what happened at AKTX last week (0914-0918)?
Weekly Report · 09/21 10:21
Akari price target adjusted at Alliance Global after transfer, reverse split
TipRanks · 09/16 12:40
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.